Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
103.67
-2.00 (-1.89%)
At close: May 14, 2025, 4:00 PM
104.49
+0.82 (0.79%)
After-hours: May 14, 2025, 7:42 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
According to 15 professional analysts, the 12-month price target for Axsome Therapeutics stock ranges from a low of $105 to a high of $216. The average analyst price target of $170.2 forecasts a 64.17% increase in the stock price over the next year.
Price Target: $170.20 (+64.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Axsome Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 7 | 7 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 15 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $200 → $180 | Strong Buy | Maintains | $200 → $180 | +73.63% | May 7, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $160 → $165 | Buy | Maintains | $160 → $165 | +59.16% | May 6, 2025 |
| Baird | Baird | Buy Maintains $160 → $162 | Buy | Maintains | $160 → $162 | +56.27% | May 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $190 → $193 | Buy | Maintains | $190 → $193 | +86.17% | Apr 29, 2025 |
| Jefferies | Jefferies | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +92.92% | Apr 7, 2025 |
Financial Forecast
Revenue This Year
627.22M
from 385.69M
Increased by 62.62%
Revenue Next Year
1.02B
from 627.22M
Increased by 62.94%
EPS This Year
-3.32
from -5.99
EPS Next Year
2.05
from -3.32
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 696.9M | 1.2B | 2.0B | ||
| Avg | 627.2M | 1.0B | 1.6B | ||
| Low | 569.4M | 865.3M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 80.7% | 92.6% | 93.4% | ||
| Avg | 62.6% | 62.9% | 51.7% | ||
| Low | 47.6% | 38.0% | 12.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | 7.90 | 17.25 | ||
| Avg | -3.32 | 2.05 | 9.21 | ||
| Low | -4.61 | -3.05 | -0.77 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 743.2% | ||
| Avg | - | - | 349.9% | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.